Indeed, the increased RSK activity in vemurafenib resistant melanoma cells went along with elevated levels of PS102-YB-1 not only in the cytoplasm, but especially in the nuclear enriched fractions of the resistant cells compared to the sensitive parental cells (Figure 5A). This evidence concerns the gene RPS6KA1 and melanoma.